Literature DB >> 12008688

Mutations of the 5alpha-steroid reductase type 2 gene in six Turkish patients from unrelated families and a large pedigree of an isolated Turkish village.

G Ocal1, P Adiyaman, M Berberoğlu, E Cetinkaya, N Akar, A Uysal, T Duman, O Evliyaoğlu, Z Aycan, S Lumbroso, C Sultan, S Lumbrasso.   

Abstract

We describe six Turkish patients with 5alpha-steroid reductase type 2 deficiency from unrelated Turkish families and a large pedigree of one of these patients who reside north-west of Anatolia. Patients NA, KS, BD and SY presented for evaluation of bilateral inguinal masses with female phenotypes. Patient ABE had penoscrotal hypospadias with male phenotype. Homozygous mutation of the 5alphaSR2 gene was identified in five of these patients by genomic DNA analysis. These mutations were Leu55Gln in exon 1 (in patients FG, BD and ABE), deltaMet157 in exon 3 (in patient NA), and splice junction abnormality in intron 1 (in patient SY). One individual (patient KS) was found to be a compound heterozygous carrier of two different mutations, Leu55Gln in exon 1 and Arg171Ser in exon 3. Patient FG had a large pedigree with the Leu55Gln mutation in exon 1. The pedigree of this family with marital consanguinity is remarkable, and possibly due to the isolation of this family because of economic and social problems. A further 85 individuals belonging to this family were analyzed for exon 1 Leu55Gln mutations in the 5alphaSR2 gene. Forty-two of these 85 individuals (49.41%) had this alteration; 11 were homozygous (8 genetic male, 3 genetic female) and 31 heterozygous (18 genetic male, genetic female) for this mutation. It was interesting to see asymptomatic homozygous female carriers. In conclusion, according to our results and those of other Turkish patients reported by different investigators, 5aSR2 gene mutation analysis, especially for Leu55Gln in exon 1 and deltaMet157 in exon 3, must be carried out in Turkish patients with male pseudohermaphroditism. Homozygous asymptomatic female carriers must be taken into consideration in this clinical entity, especially in a closed population, because of the risk of transmitting the disease to their offspring.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12008688     DOI: 10.1515/jpem.2002.15.4.411

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  6 in total

1.  A novel mutation of 5alpha-steroid reductase 2 deficiency (CD 65 ALA-PRO) with severe virilization defect in a Turkish family and difficulty in gender assignment.

Authors:  Senay Savas Erdeve; Zehra Aycan; Merih Berberoglu; Zeynep Siklar; Bulent Hacihamdioglu; Kadir Sipahi; Nejat Akar; Gonul Ocal
Journal:  Eur J Pediatr       Date:  2010-02-24       Impact factor: 3.183

2.  Molecular genetics and phenotype/genotype correlation of 5-α reductase deficiency in a highly consanguineous population.

Authors:  Meshael M Alswailem; Ohoud S Alzahrani; Lamyaa Alghofaili; Ebtesam Qasem; Mai Almohanaa; Afaf Alsagheir; Bassam Bin Abbas; Najya A Attia; Adnan Al Shaikh; Ali S Alzahrani
Journal:  Endocrine       Date:  2018-09-29       Impact factor: 3.633

3.  The IVS1-2A>G mutation in the SRD5A2 gene predominates in Cypriot patients with 5α reductase deficiency.

Authors:  N Skordis; V Neocleous; A Kyriakou; E Efstathiou; A Sertedaki; P Philibert; L A Phylactou; S Lumbroso; C Sultan
Journal:  J Endocrinol Invest       Date:  2010-05-28       Impact factor: 4.256

4.  Novel mutation of SRD5A2 gene in a patient with 5α-reductase 2 deficiency from India.

Authors:  Iram Shabir; Eunice Marumudi; Madan L Khurana; Rajesh Khadgawat
Journal:  BMJ Case Rep       Date:  2012-10-30

Review 5.  Current concepts in disorders of sexual development.

Authors:  Gönül Öçal
Journal:  J Clin Res Pediatr Endocrinol       Date:  2011

Review 6.  Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide.

Authors:  Rafael Loch Batista; Berenice Bilharinho Mendonca
Journal:  Appl Clin Genet       Date:  2020-04-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.